Literature DB >> 15306594

Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).

G Hoff1, T Grotmol, E Thiis-Evensen, M Bretthauer, G Gondal, M H Vatn.   

Abstract

BACKGROUND: Screening for colorectal cancer (CRC) using guaiac based faecal occult blood tests (FOBT) has an estimated programme sensitivity of >60% but <30% for strictly asymptomatic CRC in a single screening round. In search for improved non-invasive tests for screening, we compared a test for faecal calprotectin (PhiCal) with a human haemoglobin immunochemical FOBT (FlexSure OBT).
METHODS: In the Norwegian Colorectal Cancer Prevention (NORCCAP) trial, screenees in one screening arm were offered screening with combined flexible sigmoidoscopy (FS) and FlexSure OBT. They were also requested to bring a fresh frozen sample of stool for the PhiCal test which was performed on samples from screenees with CRC (n = 16), high risk adenoma (n = 195), low risk adenoma (n = 592), and no adenoma (n = 1518) (2321 screenees in total). A positive PhiCal test was defined by a calprotectin level > or =50 microg/g.
RESULTS: The PhiCal test was positive in 24-27% of screenees whether they had no adenoma, low risk adenoma, or high risk adenoma. Ten (63%) of 16 CRCs gave a positive PhiCal test. The total positivity rate in this population was 25% for the PhiCal test compared with 12% for FlexSure OBT, with a sensitivity for advanced neoplasia of 27% and 35%, respectively. Specificity for "any neoplasia" was 76% for the PhiCal test and 90% for FlexSure OBT.
CONCLUSIONS: In colorectal screening, the performance of the PhiCal test on a single spot from one stool sample was poorer than a single screening round with FlexSure OBT and cannot be recommended for population screening purposes. The findings indicate a place for FlexSure OBT in FOBT screening.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15306594      PMCID: PMC1774205          DOI: 10.1136/gut.2004.039032

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  17 in total

1.  Improved assay for fecal calprotectin.

Authors:  H Tøn; S Dale; J Holtlund; E Skuibina; H Schjønsby; B Johne
Journal:  Clin Chim Acta       Date:  2000-02-25       Impact factor: 3.786

2.  A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer.

Authors:  S R Cole; G P Young; A Esterman; B Cadd; J Morcom
Journal:  J Med Screen       Date:  2003       Impact factor: 2.136

3.  A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method.

Authors:  B Johne; O Kronborg; H I Tøn; J Kristinsson; P Fuglerud
Journal:  Scand J Gastroenterol       Date:  2001-03       Impact factor: 2.423

4.  Faecal calprotectin levels in a high risk population for colorectal neoplasia.

Authors:  O Kronborg; M Ugstad; P Fuglerud; B Johne; J Hardcastle; J H Scholefield; K Vellacott; V Moshakis; J R Reynolds
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

5.  Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs. hemoccult II.

Authors:  J Kristinsson; K Nygaard; E Aadland; S Barstad; J Sauar; B Hofstad; N Stray; A Stallemo; B Haug; M Ugstad; H Tøn; P Fuglerud
Journal:  Digestion       Date:  2001       Impact factor: 3.216

6.  Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380.

Authors:  D A Lieberman; D G Weiss; J H Bond; D J Ahnen; H Garewal; G Chejfec
Journal:  N Engl J Med       Date:  2000-07-20       Impact factor: 91.245

Review 7.  Stool screening for colorectal cancer: evolution from occult blood to molecular markers.

Authors:  David A Ahlquist; Anthony P Shuber
Journal:  Clin Chim Acta       Date:  2002-01       Impact factor: 3.786

8.  A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds.

Authors:  O D Jørgensen; O Kronborg; C Fenger
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

9.  Design, organization and management of a controlled population screening study for detection of colorectal neoplasia: attendance rates in the NORCCAP study (Norwegian Colorectal Cancer Prevention).

Authors:  M Bretthauer; G Gondal; K Larsen; E Carlsen; T J Eide; T Grotmol; E Skovlund; K M Tveit; M H Vatn; G Hoff
Journal:  Scand J Gastroenterol       Date:  2002-05       Impact factor: 2.423

10.  The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50-64 years.

Authors:  G Gondal; T Grotmol; B Hofstad; M Bretthauer; T J Eide; G Hoff
Journal:  Scand J Gastroenterol       Date:  2003-06       Impact factor: 2.423

View more
  21 in total

1.  A simplified, non-invasive fecal-based DNA integrity assay and iFOBT for colorectal cancer detection.

Authors:  Murugan Kalimutho; Giovanna Del Vecchio Blanco; Micaela Cretella; Elena Mannisi; Pierpaolo Sileri; Amanda Formosa; Francesco Pallone; Giorgio Federici; Sergio Bernardini
Journal:  Int J Colorectal Dis       Date:  2011-01-12       Impact factor: 2.571

Review 2.  Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis.

Authors:  Andrea Iannone; Giuseppe Losurdo; Maria Pricci; Bruna Girardi; Antonio Massaro; Mariabeatrice Principi; Michele Barone; Enzo Ierardi; Alfredo Di Leo
Journal:  J Gastrointest Cancer       Date:  2016-06

Review 3.  Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease.

Authors:  Anastassios C Manolakis; Andreas N Kapsoritakis; Elisavet K Tiaka; Spyros P Potamianos
Journal:  Dig Dis Sci       Date:  2011-01-04       Impact factor: 3.199

Review 4.  Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review.

Authors:  Bashaar Alibrahim; Mohammed I Aljasser; Baljinder Salh
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04

Review 5.  Colorectal cancer screening.

Authors:  Ramona-M McLoughlin; Colm-A O'Morain
Journal:  World J Gastroenterol       Date:  2006-11-14       Impact factor: 5.742

6.  Diagnostic value of fecal B cell activating factor in patients with abdominal discomfort.

Authors:  C Xie; R Quan; L Wang; C Chen; W Yan; Y Fu
Journal:  Clin Exp Immunol       Date:  2019-08-05       Impact factor: 4.330

Review 7.  Early detection: the impact of genomics.

Authors:  M C J van Lanschot; L J W Bosch; M de Wit; B Carvalho; G A Meijer
Journal:  Virchows Arch       Date:  2017-06-01       Impact factor: 4.064

8.  Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases.

Authors:  A Damms; S C Bischoff
Journal:  Int J Colorectal Dis       Date:  2008-07-16       Impact factor: 2.571

9.  Usefulness of fecal lactoferrin and hemoglobin in diagnosis of colorectal diseases.

Authors:  Ichiro Hirata; Masahiro Hoshimoto; Osamu Saito; Masanobu Kayazawa; Takashi Nishikawa; Mitsuyuki Murano; Ken Toshina; Fang-Yu Wang; Ryoichi Matsuse
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

10.  Fecal calprotectin levels in patients with colonic polyposis.

Authors:  Raffaele Pezzilli; Alessandra Barassi; Antonio M Morselli Labate; Sergio Finazzi; Lorenzo Fantini; Giuseppe Gizzi; Milvia Lotzniker; Valeria Villani; Gianvico Melzi d'Eril; Roberto Corinaldesi
Journal:  Dig Dis Sci       Date:  2007-04-28       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.